Dare Bioscience, Inc. DARE Cash Flow

Dare bioscience, inc. (DARE)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Operating activities:
Operating activities:
Net loss
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income (Loss) Attributable to Parent
-	-	-	-	-	-	-	-	-	-	-	-958	6,530	-672	-23,864	-511	-23,504	-18,390	-36,353	-31,360	-28,856	-23,342	0	0	0
Non-cash adjustments reconciling net loss to operating cash flows:
Depreciation
21	11	4	4	3	2	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
525	462	425	330	228	139	67	34	-881	15	-2,142	9	174	9	1,323	0	1,197	896	1,988	1,438	1,177	885	0	0	0
Non-cash operating lease cost
-85	-29	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncash rent expense
-	-	-	-	-	-	-	-	-	-	-	-	39	-	-	-	89	-41	-28	14	21	29	0	0	0
Change in carrying value of preferred stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-504	0	0	0
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	266	-	-	-	212	192	162	146	131	126	0	0	0
Amortization of debt discount and deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	903	-	-	-	351	739	0	0	0	-	-	-	-
Loss on disposal of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Impairment of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Gain on asset sale
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Impairment of goodwill
-	-	-	-	-	5,187	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Other receivables
-59	201	-42	468	137	-253	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable, prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Prepaid expenses
2,857	322	220	90	313	91	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current assets
-	-	-	-	-	-193	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other non-current assets
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable, prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-342	0	0	0	-	-	-	-
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-
Accounts payable
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
0	-	-	-	0	-	-	-	-	-	-	546	-943	-0	-658	16	279	516	698	1,179	-527	341	0	0	0
Accrued expenses
154	621	602	394	151	-27	0	0	0	-	-	-	-1,617	-	-	-	3,320	3,283	2,859	889	1,439	1,419	0	0	0
Deferred grant funding
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred license revenue
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-16,604	-13,315	-12,217	-11,760	-11,458	-10,268	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-349	2,887	-372	-23,982	-471	-21,345	-16,026	-29,313	-26,904	-23,336	-19,061	0	0	0
Investing activities:
Purchases of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	607	277	250	294	240	225	0	0	0
Financing activities:
Net proceeds from issuance of common stock
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	40	0	0	0
Decrease in restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Proceeds from the sale of assets
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	0	1,742	0	-348	0	-550	-337	-480	-524	-210	-185	0	0	0
Financing activities:
Proceeds from the exercise of common stock warrants
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the exercise of stock options
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of common stock
-	-	-	-	-	-	-	-	-	-	-	-	939	-	-	-	110	2,480	2,628	2,479	2,524	140	0	0	0
Proceeds from loan payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,000	0	0	0	-	-	-	-
Proceeds from issuance of convertible promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,500	0	0	0
Net cash provided by financing activities
12,039	5,151	5,149	5,068	-85	10,111	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net change in cash and cash equivalents
1,542	-2,025	-7,102	-6,815	-12,120	-753	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on loan payable
-	-	-	-	-	-	-	-	-	-	-	-	19,067	-	-	-	1,332	3,321	4,783	5,629	6,457	3,348	0	0	0
Cash paid for debt issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	359	0	0	0	-	-	-	-
Payment of end of term charge on loan payable
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	0	-19,535	-	-	-	35,882	50,885	49,638	48,633	71,394	64,932	0	0	0
Net change in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-48,487	-	-	-	4,199	24,734	19,845	21,205	47,848	45,686	0	0	0
Supplemental disclosure of non-cash operating and financing activities:
Operating right-of-use assets obtained in exchange for new operating lease liabilities
351	583	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental cash flow information Interest paid
-	-	-	-	-	-	-	-	-	-	-	-	1,190	-	-	-	1,209	1,000	797	609	437	400	0	0	0